Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 3/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | SDCBP | O00560 | 1/20 | 0.42 |
| ▸ | SDC2 | P34741 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570189 | 0.87 | HDAC1 (0.63) | HDAC1EPHX2NR1H4NAMPTHPN | |
| SCHEMBL2574484 | 0.86 | HDAC1 (0.59) | HDAC1EPHX2NR1H4NAMPTHPN | |
| SCHEMBL2806364 | 0.84 | ROCK2 (0.53) | HDAC1ATRNAMPTERN1 | |
| SCHEMBL9726455 | 0.84 | EPHX2 (0.62) | HDAC1ATREPHX2NR1H4NAMPT | |
| SCHEMBL2572747 | 0.83 | HDAC1 (0.56) | HDAC1NAMPTHPNL3MBTL1SDCBP | |
| SCHEMBL2570147 | 0.82 | HDAC1 (0.62) | HDAC1NAMPTHPNL3MBTL1SDCBP | |
| SCHEMBL1691047 | 0.81 | HDAC1 (0.67) | HDAC1EPHX2NR1H4NAMPTL3MBTL1 | |
| SCHEMBL31716389 | 0.81 | HDAC1 (0.58) | HDAC1NAMPTHPNL3MBTL1SDCBP | |
| SCHEMBL3278301 | 0.81 | HDAC1 (0.58) | HDAC1NAMPTHPNL3MBTL1SDCBP | |
| SCHEMBL2567487 | 0.80 | HDAC1 (0.50) | HDAC1ATRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | HDAC1 2556/4885ATR 4514/4885EPHX2 1259/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | HDAC1 2720/4885ATR 4334/4885EPHX2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.